An Enzyme Variant and a Drug Dose
A patient is genotyped before starting a drug that is inactivated by a liver enzyme. The patient is heterozygous for a variant allele that produces an enzyme with about 30% of normal catalytic activity; the other allele is the normal (wild-type) version. The drug is normally cleared quickly, and standard dosing assumes two fully functional alleles. The patient also takes a second drug that competitively inhibits the same enzyme. Within a week of standard dosing the patient develops side effects consistent with drug accumulation. A note in the chart says 'heterozygote, so half normal activity, probably fine.'
1. Evaluate the chart note. Is 'half normal activity' a safe assumption here, and why or why not?
Read the worked answer
It is not safe. Heterozygosity does not mean 50% activity. If one allele makes an enzyme with 30% of normal catalytic activity, the heterozygote's total activity depends on how the two alleles combine. If the variant protein is simply less active but stable, the cell might have roughly (100% + 30%)/2 = 65% of normal, which is often enough. But if the variant protein is unstable, misfolded, or interferes with the normal protein (dominant-negative behaviour, common in multimeric enzymes), activity can fall well below 50%. The note assumes a simple additive model without evidence. The observed side effects are the real evidence: the patient is accumulating drug, so clearance is inadequate in practice regardless of the theoretical percentage.
2. How does the second, competitively inhibiting drug change the picture, and what does that imply for dosing?
Read the worked answer
Competitive inhibition raises the apparent Km of the enzyme: at a given drug concentration the enzyme works below its uninhibited rate. So the patient now has reduced enzyme amount/quality from the genotype and reduced enzyme function from the inhibitor, and these effects multiply rather than simply add. With standard dosing the concentration of the substrate drug rises, which partly overcomes competitive inhibition, but the ceiling is set by the remaining catalytic capacity. The combined effect explains the rapid accumulation. Dosing should be reduced and guided by measured drug levels rather than by genotype alone, and the interacting drug should be swapped if a non-inhibiting alternative exists.
3. If the patient were homozygous for the variant allele instead, what would you expect and why?
Read the worked answer
Two copies of the 30%-activity allele would leave the patient with roughly 30% of normal activity (less if the protein is unstable), a much more severe reduction than the heterozygote. Clearance would be markedly slower even without the inhibitor, and standard doses would be likely to cause toxicity quickly. This is the classic poor-metaboliser phenotype. The practical point is that genotype predicts direction and rough magnitude, but the actual phenotype depends on protein stability, the inhibitor, liver function and other drugs, so levels should be measured rather than inferred from the genotype label alone.